Immunoprecise Antibodies Ltd IPA

ImmunoPrecise Reports Financial Results and Recent Business

[AveragePenny]

Third Quarter Fiscal Year 2022 Financial Summary*
(All comparisons are to the period ended January 31, 2022)

• The Company achieved Project revenue of $4.1 million, an increase of $0.7 million or 22.6% as compared to Project revenue of $3.3 million from the same year ago period.
• The Company’s total revenue of $4.8 million was an increase of $0.3 million or 6.6% as compared to total revenue of $4.5 million from the same year ago period.
• The Company, primarily through its subsidiary Talem Therapeutics LLC, invested $1.8 million in strategic research and development costs as compared to an investment of nil in the same year ago-period.
• The Company recorded a net loss of $3.8 million, as compared to net loss of $1.3 million as compared to the same year-ago period.
• As of January 31, 2022, the Company held cash of $33.0 million.

https://www.businesswire.com/news/home/20220316005566/en/ImmunoPrecise-Reports-Financial-Results-and-Recent-Business-Highlights-for-Third-Quarter-Fiscal-Year-2022